References
- Braak H, Del Tredici K, Bratzke H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease. J Neurol. 2002;249:1–5.
- Ray Chaudhuri K, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
- Jost WH. Autonomic dysfunctions in idiopathic Parkinson’s disease. J Neurol. 2003;250(Suppl.1):28–30.
- Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649. .
- Merola A, Romagnolo A, Comi C, et al. Prevalence and burden of dysautonomia in advanced Parkinson’s disease. Mov Disord. 2017;32(5):796–797.
- Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287–297.
- Strano S, Fanciulli A, Rizzo M, et al. Cardiovascular dysfunction in untreated Parkinson’s disease: A multi-modality assessment. J Neurol Sci. 2016;370:251–255.
- Jost WH, Augustis S. Severity of orthostatic hypotension in the course of Parkinson’s disease: no correlation with the duration of the disease. Parkinsonism Rel Disord. 2015;21(3):314–316.
- Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Baroreflex dysfunction. N Engl J Med. 2020;382(2):163–178.
- Jost WH, Del Tredici K, Landvogt C, et al. Importance of 123I-metaiodobenzylguanidin (MIBG) scintigraphy / SPECT for diagnosis and differential diagnostics of Parkinson syndromes. Neurodegenerative Dis. 2010;7(5):341–347.
- Bellon AK, Jost WH, Schimrigk K, et al. Hormonelle regulation beim Parkinson syndrom. Dtsch Med Wschr. 1996;121(36):1077–1083.
- Hou L, Li Q, Jiang L, et al. Hypertension and diagnosis of Parkinson’s disease: A meta-analysis of cohort studies. Front Neurol. 2018;9:162.
- Sommer S, Aral-Becher B, Jost W. Nondipping in Parkinson’s disease. Parkinson’s Dis. 2011;2011:1–5. ID 897586.
- Espay AJ, LeWitt PA, Hauser RA, et al., Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol. 2016;15(9):954–966 .
- Milazzo V, Di Stefano C, Vallelonga F, et al. Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease. Parkinsonism Relat Disord. 2018;56:82–87.
- Jost WH, Fiesel T, Becht B, et al. Influence of levodopa on orthostatic hypotension in Parkinson’s disease. Neurol Neurochir Pol. 2020;54. doi:10.5603/PJNNS.a2020.0019.
- Goldstein DS, Pechnik S, Holmes C, et al. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension. 2003;42(2):136–142.
- Jost WH, Brück C. Drug interactions in the treatment of Parkinson’s disease. J Neurol. 2002;249(Suppl. 3):24–29.
- Jordan J, Fanciulli A, Tank J, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American autonomic society, European federation of autonomic societies, and the European society of hypertension. J Hypertens. 2019;37(8):1541–1546.
- Schoffer KL, Henderson RD, O’Maley K, et al. Nonpharmocological treamtent, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–1549.
- Byun JI, Moon J, Kim DY, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology. 2017;89(10):1078–1086.
- Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33(3):372–90R.
- Heranval A, Lefaucheur R, Fetter D, et al. Drugs with potential cardiac adverse effects: retrospective study in a large cohort of parkinsonian patients. Rev Neurol (Paris). 2016;172(4–5):318–323.
- Sempere AP, Duarte J, Cabezas C, et al. Parkinsonism induced by amlodipine. Mov Disord. 1995;10(1):115–116. .
- Lee YC, Lin CH, Wu RM, et al. Antihypertensive agents and risk of Parkinson’s disease: a nationwide cohort study. PLoS One. 2014;9(6):e98961.
- Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67(5):600–606.
- Williams B, Mancia G, Spiering W, et al. Practice Guidelines for the management of arterial hypertension of the European society of cardiology and the european society of hypertension. Blood Press. 2018;27(6):314–340.